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In Brief
Axon degeneration is a critical feature of
many neurodegenerative diseases.
Yamagishi and Tessier-Lavigne report
that the E3 ubiquitin ligase component
Skp1a promotes degeneration of injured
axons by regulating the NAD+-producing
enzyme Nmnat2 in axons. Rapid
depletion of axonal Nmnat2 after injury
induces a local energy deficit and axon
degeneration.
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Axon degeneration is a tightly regulated, self-
destructive program that is a critical feature of
many neurodegenerative diseases, but themolecular
mechanisms regulating this program remain poorly
understood. Here, we identify S-phase kinase-asso-
ciated protein 1A (Skp1a), a core component of a
Skp/Cullin/F-box (SCF)-type E3 ubiquitin ligase com-
plex, as a critical regulator of axon degeneration after
injury in mammalian neurons. Depletion of Skp1a
prolongs survival of injured axons in vitro and in
the optic nerve in vivo. We demonstrate that Skp1a
regulates the protein level of the nicotinamide
adenine dinucleotide (NAD)+ synthesizing enzyme
nicotinamide mononucleotide adenylyltransferase 2
(Nmnat2) in axons. Loss of axonal Nmnat2 contrib-
utes to a local ATP deficit that triggers axon degener-
ation. Knockdown of Skp1a elevates basal levels of
axonal Nmnat2, thereby delaying axon degeneration
through prolonged maintenance of axonal ATP.
Consistent with Skp1a functioning through regula-
tion of Nmnat2, Skp1a knockdown fails to protect
axons fromNmnat2 knockdown. These results illumi-
nate the molecular mechanism underlying Skp1a-
dependent axonal destruction.INTRODUCTION
Axon degeneration is a critical feature of many neurodegenera-
tive diseases, such as Alzheimer’s disease, amyotrophic lateral
sclerosis, and Parkinson’s disease (Conforti et al., 2014; Wang
et al., 2012). Wallerian degeneration is one type of axon degen-
eration commonly observed in disease. It is best known as the
program that results in the rapid and stereotyped degeneration
of axon segments distal to an injury site, but it also contributes
to axon degeneration in response to additional insults such as
those provided by the microtubule-targeting chemotherapy
drug vincristine and the mitochondrial toxin rotenone (Coleman
and Freeman, 2010). Insights into the molecular program that774 Cell Reports 17, 774–782, October 11, 2016 ª 2016 The Authors
This is an open access article under the CC BY-NC-ND license (http://regulates Wallerian degeneration came from discovery of a
mouse mutant that expresses the Wallerian degeneration slow
(Wlds) protein, which potently prolongs axon survival after injury.
The Wlds protein consists of an N-terminal portion derived from
the E4 ubiquitin ligase Ube4b fused to the full-length coding
sequence of nicotinamide mononucleotide adenylyltransferase
1 (Nmnat1) (Mack et al., 2001). The protective activity of Wlds
is attributed to increased axonal NMNAT activity and can be
mimicked by transgenic delivery of proteins with NMNAT activity
to the axon (Babetto et al., 2010; Sasaki et al., 2009). Importantly,
the Wlds protein delays axon degeneration in many neurode-
generative disease models, suggesting that there is a shared
mechanism of axonal loss in neurodegenerative disorders and
Wallerian degeneration (Conforti et al., 2014; Wang et al., 2012).
Nmnat2, one of the three NMNAT isoforms in mouse, is
required to maintain axon integrity. Depletion of Nmnat2, but
not other NMNAT isoforms, triggers Wallerian-like axon degen-
eration in cultured mouse sympathetic neurons (Gilley and Cole-
man, 2010). Further, central and peripheral axons are truncated
in Nmnat2 mutant mice, indicating that Nmnat2 plays an essen-
tial role in axon survival during development (Hicks et al., 2012;
Gilley et al., 2013). Axonal Nmnat2 protein has a short half-life
and is rapidly degraded after injury, suggesting that early loss
of Nmnat2 triggers Wallerian degeneration in distal axons (Gilley
and Coleman, 2010; Milde et al., 2013). Indeed, it has been sug-
gested that Phr1/highwire, an evolutionarily conserved E3 ubiq-
uitin ligase, plays a critical role in Wallerian degeneration by
regulating axonal NMNAT levels in both mice and flies (Xiong
et al., 2012; Babetto et al., 2013). Although these studies indicate
that NMNAT protein in axons is required for axon integrity, how
NMNAT contributes to axon survival and how loss of NMNAT
leads to axonal destruction remain unknown.
Skp1a (S-phase kinase-associated protein 1A) is a core
component of an evolutionarily conserved Skp/Cullin/F-box
(SCF)-type E3 ubiquitin ligase complex. SCF complexes typically
include a member from each of the Skp1, Cullin, Rbx1, and
F-box protein families. However, it has been suggested that
Skp1a can form an atypical SCF-like E3 ubiquitin ligase complex
with E3 Phr1/PAM and the F-box protein Fbxo45, raising the
possibility that Skp1a works with Phr1 and Fbxo45 in axon
degeneration after injury (Saiga et al., 2009). Indeed, it was re-
ported recently that the Drosophila Skp1a homolog, SkpA, func-
tions during synaptic development and axonal maintenance in.
creativecommons.org/licenses/by-nc-nd/4.0/).
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flies (Brace et al., 2014). In this report, through an unbiased RNA
interference screen, we identify Skp1a as an essential regulator
of axon degeneration after injury in mammalian neurons in vitro
and in vivo. We demonstrate that Skp1a regulates axonal
Nmnat2. Depletion of Skp1a increases basal Nmnat2 in axons,
prolonging axon survival after injury. Further, depletion of axonal
Nmnat2 after axotomy leads to a local energy deficit that triggers
axon degeneration.
RESULTS
Skp1a Promotes Axon Degeneration after Physical and
Chemical Insults in Cultured Sensory Neurons
To identify genes required for Wallerian degeneration, we
screened a small interfering RNA (siRNA) library that targets
the mouse genome (>20,000 genes) using cultured dorsal root
ganglion (DRG) neurons (Y.Y. and M.T.-L., unpublished data).
In the screen we found that siRNA pools against Skp1a-pro-
tected axons from degeneration after transection (Figure S1A).
To exclude the possibility of off-target effects, we individually
introduced three different short hairpin RNAs (shRNAs) targeting
discrete sequences in the Skp1a transcript into DRG neurons
using lentivirus-mediated transduction. In neurons expressing
control shRNA, axon segments distal to the transection site de-
generated within 12 hr of axotomy. In contrast, axons in neurons
expressing shRNAs targeting Skp1awere significantly protected
from degeneration (Figures S1B–S1D), with60% of distal axon
segments preserved 24 hr post-axotomy (Figures 1A and 1B;
Figure S1E). Importantly, neurons expressing Skp1a shRNAs
showed concomitant reductions in Skp1a protein. Co-expres-
sion of an RNAi-resistant Skp1a rescued degeneration in
Skp1a shRNA-expressing neurons, further excluding the possi-
bility of a non-specific effect of shRNA expression (Figures 1C–
1E). To biochemically characterize axon degeneration after
axotomy, we analyzed the time course of protein degradation
in axon segments distal to the transection site (Figure 1F). In con-
trol axons, neurofilament-L and neurofilament-M were rapidly
degraded within 24 hr after axotomy. In contrast, neurofilaments
are preserved in Skp1a-depleted neurites, consistent with a role
for Skp1a in axon degeneration after axotomy. To test whether
Skp1a plays a similar role after other types of axonal insult,
we examined the toxic effects of vincristine and rotenone.
Both drugs induce Wallerian-like degeneration, and axons are
completely fragmented within 24 hr (Figures 1G and 1H).
Consistent with previous findings of a role for the Wallerian
degeneration pathway in vincristine- and rotenone-induced
axon degeneration, Skp1a knockdown significantly delayed
axonal destruction induced by these chemical toxins. TakenFigure 1. Skp1a Functions in Cultured Sensory Neurons to Promote A
(A) Axon degeneration 24 hr after axotomy was visualized by immunostaining for
(B) Axon degeneration was quantified at indicated time points after axotomy (n =
(C) Axon degeneration 12 hr after axotomy was visualized by immunostaining fo
(D) Axon degeneration shown in (C) was quantified (n = 3 for each condition). *p
(E) Axonal Skp1a levels in DRG neurons expressing wild-type (WT) or RNAi-resis
(F) Axonal protein was harvested from control or Skp1a shRNA-expressing neuron
(G) Axon degeneration 24 hr after 40 nM vincristine or 5 mM rotenone was visual
(H) Axon degeneration shown in (G) was quantified (n = 3 for each condition). *p
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both physically and chemically induced axon degeneration.
Skp1a Regulates Axon Degeneration of Optic Nerves
after Injury In Vivo
We used an optic nerve injury paradigm (Yang et al., 2015) to
assess the role of Skp1a in injury-induced axon degeneration
of retinal ganglion cells (RGCs) in vivo. Skp1a mRNA is detected
in the ganglion cell layer by in situ hybridization, indicating that
Skp1a is expressed by RGCs (Figure 2A). To deplete Skp1a
in optic nerves, we injected adeno-associated virus (AAV2) ex-
pressing shRNA against Skp1a or control shRNA intravitreally.
The virus also contains a TdTomato reporter to identify the axons
of transduced RGCs. Most TdTomato-positive axons of RGCs
targeted by the control shRNA showed signs of degeneration
(large swelling and/or fragmentation) 3 days after optic nerve
crush, and all axons had fragmented by 6 days (Figure 2B). In
contrast, axon degeneration of RGCs targeted by shRNA against
Skp1a was significantly delayed after optic nerve crush, with
more than 50% of TdTomato-labeled axons intact 3 days after
crush (Figures 2B and 2C). These results are consistent with
the Skp1a cell autonomously promoting Wallerian degeneration
in vivo.
Skp1a Promotes Wallerian Degeneration via Regulation
of Axonal Nmnat2
Of the three NMNATs in mice and humans, Nmnat2 has been
identified as an essential axon survival factor required for nerve
development (Gilley and Coleman, 2010; Conforti et al., 2011;
Hicks et al., 2012; Gilley et al., 2013). Nmnat2 has a very short
half-life in axons and is rapidly depleted in severed axons (Gilley
and Coleman, 2010; Milde et al., 2013). Nmnat2 is transported
from cell bodies to axons (Milde et al., 2013); thus, it has been
suggested that axon degeneration may be triggered by blocking
that transport of Nmnat2. To examine whether Skp1a contrib-
utes to the rapid depletion of axonal Nmnat2 after axotomy,
we quantified axonal Nmnat2 levels before and after axotomy
in DRG neurons expressing control shRNA or Skp1a-targeting
shRNA (Figures 3A and 3B). Levels of axonal Nmnat2 in Skp1a
knockdown neurons were higher than in control neurons before
axotomy (Figures 3A and 3B), indicating that Skp1a is an impor-
tant regulator of basal Nmnat2 levels in axons. Levels of axonal
Nmnat2 declined rapidly in both control and Skp1a shRNA-tar-
geted neurons after axotomy; when normalized to baseline
levels, the rate of Nmnat2 decline was similar in both (Figure 3B).
These results suggest that the delay in axon degeneration
conferred by Skp1a knockdown results from elevated basal
expression of axonal Nmnat2 rather than a slowing of its loss.xon Degeneration after Both Physical and Chemical Insults
Tuj1 and NF-M. Scale bar, 100 mm.
3 for each condition). Error bars are ± SD. See also Figure S1E.
r Tuj1. Scale bar, 100 mm.
< 0.01, t test. Error bars are ± SD.
tant (RR) Skp1a with or without shRNA were examined by immunoblotting.
s at indicated time points after axotomy and subjected to immunoblot analysis.
ized by immunostaining for Tuj1 and NF-M. Scale bar, 100 mm.
< 0.01, t test. Error bars are ± SD.
Figure 2. Skp1a Regulates Degeneration of Injured RGC Axons In Vivo
(A) mRNA expression of Skp1a in P6 mouse retina was examined by in situ hybridization. Scale bar, 100 mm.
(B) RGCs were transduced with knockdown vectors (see Experimental Procedures). Representative maximum intensity projection images of TdTomato-labeled
RGC axons at the indicated time points after optic nerve crush are shown. Scale bar, 100 mm.
(C) Quantification of axon degeneration of TdTomato-labeled RGC axons (n = 3 for each condition). *p < 0.01, t test. Error bar is ± SD.
GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer.They also imply that Nmnat2 is degraded in a Skp1a-indepen-
dent manner, which is consistent with previous results showing
that acute application of proteasome inhibitors fails to protect
DRG axons after axotomy (Yang et al., 2013).
To test whether Skp1a delays Wallerian degeneration by
increasing axonal Nmnat2 levels, we knocked down Nmnat2
after Skp1a knockdown in DRG neurons. DRGs were cultured
for 5 days after Skp1a shRNA transduction, thereby raising
Nmnat2 levels in axons. Neurons were then subjected to Nmnat2
knockdown and cultured for an additional 2 days, at which time
axons were severed. Knockdown of Nmnat2 reversed the protec-
tion afforded by Skp1a knockdown, consistent with Skp1a acting
bymodulatingNmnat2 levels (Figures3Cand3D).Thismechanism
isconsistentwith aprevious reportdemonstrating that lossofPhr1
delays Wallerian degeneration by regulating Nmnat2 levels (Ba-
betto et al., 2013). Because Phr1 has been suggested to form a
complex with Skp1a and the F-box protein Fbxo45 (Saiga et al.,
2009) (Figure 3E), we examined whether Phr1 and/or Fbxo45
knockdown showed a phenotype similar to Skp1a knockdown.
Knockdown of either Fbxo45 or Phr1 delayed axon degenerationfollowingaxotomy,andNmnat2knockdown restoredaxondegen-
eration in neurons expressing either Fbxo45 or Phr1 shRNA (Fig-
ures 3C and 3D; Figure S2). Taken together, these results indicate
that Skp1a, Phr1, and Fbxo45 all function in axon degeneration
after injury by regulating Nmnat2 levels.
Loss of Nmnat2 Causes a Local Energy Deficit in Axons
Previous studies have suggested that local energy deficits
(nicotinamide adenine dinucleotide [NAD]+ and ATP depletion)
trigger axon degeneration following injury (Yang et al., 2015;
Gerdts et al., 2015; Wang et al., 2005). Nmnat2 is an NAD+-
producing enzyme; therefore, we hypothesized that the rapid
loss of Nmnat2 induces a local deficiency of NAD+ and ATP
that triggers axon degeneration. Consistent with this idea, deple-
tion of Nmnat2 in sympathetic neurons causes spontaneous
axon degeneration (Gilley and Coleman, 2010). Similarly, we
found that knockdown of Nmnat2 causes spontaneous axon
degeneration in DRG neurons and a corresponding decrease in
axonal ATP (Figures 4A–4D). Overexpression of a cytoplasmic
version of Nmnat1 blocks axon degeneration after knockdownCell Reports 17, 774–782, October 11, 2016 777
Figure 3. Skp1a Functions in Axon Degeneration via Regulation of Axonal Nmnat2
(A) Axonal protein was harvested from control or Skp1a shRNA-expressing neurons at indicated time points after axotomy and subjected to immunoblot analysis.
(B) Axonal Nmnat2 shown in (A) was quantified at the indicated time points after axotomy using ImageJ (n = 4 for each condition). *p < 0.05, **p < 0.01, t test. Error
bars are ± SD.
(C) Axon degeneration of DRG neurons expressing each shRNA was visualized by immunostaining of Tuj1 at the indicated time points after axotomy. Scale bar,
100 mm.
(D) Axon degeneration shown in (C) was quantified (n = 3 for each condition). Error bars are ± SD.
(E) Schematic model for the Skp1a-Phr1-Fbxo45 complex.of Nmnat2, consistent with Nmnat2 knockdown resulting in a
shortage of NAD+ production in depleted axons. Next, we tested
whether axon degeneration resulting fromNmnat2 knockdown is
dependent onaxonal ATPdepletion. If the spontaneousdegener-
ation is caused by depletion of ATP in axons, increasing ATP pro-
duction should prevent axon degeneration. To test this idea, we
stimulated ATP production by supplementing the culture media
withmethyl-pyruvate. Treatment of axonswith 10mMmethyl-py-
ruvate inhibits ATP depletion and axon degeneration in neurons778 Cell Reports 17, 774–782, October 11, 2016expressing Nmnat2 shRNA (Figures 4B–4D). Taken together,
these results demonstrate that loss of Nmnat2 induces sponta-
neous axon degeneration through a local energy deficit.
SCF-Dependent Regulation of Nmnat2 Levels Mediates
Axon Degeneration after Injury through a Local Energy
Deficit
Our results support a model in which an atypical ubiquitin ligase
complex comprising Skp1a, Phr1, and Fbxo45 regulates basal
(legend on next page)
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levels of Nmnat2 in axons, and depletion of this ubiquitin ligase
prolongs axon survival after injury. To examinewhether depletion
of this ubiquitin ligase delays the local energy deficit in distal
axons after injury, we knocked down Skp1a and quantified the
axonal ATP level in distal axons after axotomy in DRG neurons
in vitro. After axotomy, the ATP level in distal axons showed
a rapid decrease, which was prevented by expression of a cyto-
plasmic versionofNmnat1 (FigureS3). Importantly, expression of
Skp1a or Phr1 shRNA significantly delayed this local ATP deple-
tion (Figure 4E). This suggests that SCF-dependent Nmnat2
regulation contributes to a local energy deficit in distal axons after
axotomy. Taken together, our results suggest that Skp1a/Phr1/
Fbxo45 contributes to Wallerian degeneration by regulating
axonal energy levels through regulation of axonal Nmnat2. It
was previously reported that the rapid depletion of axonal
Nmnat2 after axotomy seen in wild-type axons also occurs in
Sarm1 knockout (KO) axons even though degeneration of those
axons is largely prevented (Gilley et al., 2015); together with our
results, this suggests that Skp1a and Nmnat2 work upstream
and/or in parallel to Sarm1 activation. An artificially dimerizable
Sarm1-Toll/interleukin-1 receptor (TIR) domain (FKBP(F36V)-
TIR [Yang et al., 2015]) was expressed in combination with
Skp1a knockdown in DRGneurons to further investigate the rela-
tionship between Skp1a and Sarm1. FKBP(F36V)-TIR can be
dimerized by the chemical AP20187 (Yang et al., 2015). Forced
dimerization of Sarm1-TIR by treatment of neurons expressing
FKBP(F36V)-TIRwith AP20187 induced rapid depletion of axonal
ATP and degeneration of distal axons (Figures 4F–4H). Impor-
tantly, expression of Skp1a shRNA did not delay their degenera-
tion, suggesting that activatingSarm1-mitogen-activated protein
kinase (MAPK) signaling is sufficient to induce axondegeneration
without the regulation of axonal Nmnat2 by Skp1a.
DISCUSSION
Despite axon degeneration being a key pathological feature of
many neurodegenerative disorders, the molecular mechanisms
underlying the axonal death programs remain incompletely
understood. Here,we identify Skp1a, a core component of
SCF-type ubiquitin ligase complexes, as a critical regulator of
this program in mammalian neurons. Depletion of Skp1a
potently protects injured DRG axons in vitro and RGC axons
in vivo. The function of Skp1a in axon degeneration is not limitedFigure 4. Nmnat2 Degradation Induces a Local Energy Deficit that Trig
(A) The efficiency of lentiviral-shRNA-mediated knockdown of Nmnat2 was exam
embryonic DRG neurons.
(B) Representative images of Tuj1-stained cultured sensory neurons expressin
methyl-pyruvate.
(C) Axon degeneration of cultured sensory neurons shown in (B) was quantified (
are ± SD.
(D) Axonal ATP levels of cultured sensory neurons expressing the indicated shRNA
t test. Error bars are ± SD.
(E) Axonal ATP levels of cultured sensory neurons expressing the indicated shR
condition). *p < 0.01, t test. Error bars are ± SD.
(F) Representative images of Tuj1-stained cultured sensory neurons expressing t
(G) Axon degeneration of cultured sensory neurons shown in (F) was quantified (
(H) Axonal ATP levels of cultured sensory neurons expressing FKBP(F36V)-TIR an
addition (n = 3 for each condition). Error bars are ± SD.
780 Cell Reports 17, 774–782, October 11, 2016to axon degeneration after traumatic injury because depletion of
Skp1a also delays axon degeneration after chemical insults
(vincristine and rotenone treatment), suggesting that Skp1a
works in a common pathological axon degeneration program.
The canonical SCF-type ubiquitin ligase complex consists of
Skp1, Cullin, Rbx1, and an F-box protein. However, Skp1a can
also form an atypical ubiquitin ligase complex with the Phr1 ubiq-
uitin ligase and the F-box protein Fbxo45 without Cullin or Rbx1
family members (Saiga et al., 2009). Previous studies showed
that mouse Phr1 and its Drosophila homolog highwire function
in Wallerian degeneration (Xiong et al., 2012; Babetto et al.,
2013). Recently, the Drosophila Skp1a homolog, SkpA, was also
shown to regulate axon degeneration following injury, suggesting
that Skp1a plays a critical role in Phr1 ubiquitin ligase function
(Brace et al., 2014). A previous study identified the axon survival
factor Nmnat2 as a downstream target of Phr1, although endoge-
nous Nmnat2 protein was not detected in axons (Babetto et al.,
2013). We show clearly that the endogenous Nmnat2 level in
axons is higher in Skp1a knockdown neurons, both before and
after axotomy (Figures 3A and 3B). Furthermore, the axon protec-
tionprovidedbySkp1aorPhr1depletionwasabrogatedbysimul-
taneous partial depletion of Nmnat2 (Figures 3C and 3D). These
results support the idea that Skp1a is essential for regulation of
Phr1 activity toward Nmnat2. However, direct ubiquitination
of Nmnat2 has not been detected in mammalian neurons, and
recent evidence argues against a role for the proteasome in acute
regulation of DRG axon degeneration (Yang et al., 2013). There-
fore, it remains to be revealed whether the basal Nmnat2 level
in axons is directly regulated by the ubiquitin-proteasome
pathway. In addition, the Nmnat2 level still decreases rapidly
after axotomy in Skp1a-depleted neurons, implying that an
additional mechanism eliminates Nmnat2 from axons after injury.
Loss of function of the adaptor protein Sarm1 and its down-
stream MAPK pathway components significantly delays degen-
eration of injured axons (Yang et al., 2015; Osterloh et al., 2012;
Gerdts et al., 2013). Sarm1-MAPK signaling causes NAD+ and
ATP depletion locally in the distal portion of the injured axons,
which then triggers degeneration (Yang et al., 2015; Gerdts
et al., 2015). Importantly, Sarm1 deletion or Wlds protein overex-
pression delays Wallerian degeneration but does not inhibit the
rapid depletion of Nmnat2 protein in injured axons, suggesting
that Sarm1-MAPK accelerates NAD+ consumption rather than
decreases NAD+ production (Yang et al., 2015; Gerdts et al.,gers Axon Degeneration
ined by immunoblot analysis of cell body or axonal proteins harvested from
g the indicated shRNAs 4 days after transduction. Scale bar, 100 mm. MP,
n = 3 for each condition). *p < 0.01, two-way ANOVA post hoc test. Error bars
s were measured 3 days after transduction (n = 3 for each condition). *p < 0.01,
NAs were measured at indicated time points after axotomy (n = 3 for each
he indicated shRNAs and FKBP(F36V) or FKBP(F36V)-TIR. Scale bar, 100 mm.
n = 3 for each condition). *p < 0.01, t test. Error bars are ± SD.
d the indicated shRNAs were measured at indicated time points after AP20187
2015). In this study, we show that Nmnat2 depletion in cultured
sensory neurons induces axonal ATP depletion followed by
axon degeneration. Exogenous supplementation of the meta-
bolic fuel methyl-pyruvate stimulates ATP production and
significantly blocks axon degeneration (Figures 4B and 4C).
Furthermore, Skp1a or Phr1 depletion, which increases basal
Nmnat2 protein level in axons, significantly delays axonal ATP
depletion following injury (Figure 4E). In contrast, knockdown
of Skp1a did not delay axon degeneration after forced dimer-
ization of the Sarm1-TIR domain (Figures 4F and 4G). This sug-
gests that Skp1a and its regulation of axonal Nmnat2 function
upstream of Sarm1-MAPK signaling.
In summary, we identify Skp1a as a regulator of axon
degeneration and demonstrate that Skp1a-dependent Nmnat2
regulation is critical for axon integrity. Wlds expression signifi-
cantly delays axon degeneration in many neurodegenerative
disease models. Both Wlds expression and Skp1a depletion in-
crease NMNAT activity in axons; therefore, they probably use a
common mechanism to protect axons, i.e., delaying the axonal
energy deficit. As such, Skp1a could be a potential therapeutic
target to ameliorate axon degeneration in neurodegenerative
disorders.
EXPERIMENTAL PROCEDURES
Neuronal Cultures and Analyses on Prepared Axons
Silicon dividers were set up on poly-D-lysine (PDL)/laminin-coated 6-well or
12-well plates. DRGs were dissected from embryonic day (E)12.5 mouse
embryos and dissociated in 0.05% trypsin-EDTA. Dissociated neurons were
plated in Neurobasal supplemented with 2% B-27, 0.45% D-glucose, 1%
GlutaMAX, 100 U/mL penicillin, and 100 U/mL streptomycin. Silicon dividers
were removed 3 hr later. On day 1 in vitro (DIV1), the cultures were fed with
fresh Neurobasal/B-27 medium containing 5 mM 5-fluoro-20-deoxyuridine
and 5 mM uridine to inhibit the growth of non-neuronal cells. On DIV4, cells
were transduced with lentivirus-expressing shRNAs. Cultures were axotom-
ized or treated with chemicals on DIV10–12. For western blot of axonal pro-
teins, cell bodies and axons were separately lysed in lysis buffer (150 mM
NaCl, 50 mM Tris [pH 7.6], 5 mM EDTA, 0.1% Triton X-100, complete protease
inhibitor cocktail [Roche]). The protein concentration of each sample was
measured with 660 nm protein assay (Pierce); 2 mg protein was loaded in
each well and subjected to SDS-PAGE and western blot analysis. For ATP
measurement, neuronal cell bodies and proximal axon were removed, and
axons were subjected to ATP measurement with ATPlite (PerkinElmer).
Intravitreal Injection and Optic Nerve Crush
All surgical procedures in mice were performed in compliance with the proto-
col approved by the Institutional Animal Care and Use Committee (IACUC)
of The Rockefeller University. RGCs were transduced by AAV2 delivered via
intravitreal injection. Four weeks after injection, optic nerve crush was per-
formed for 10 s using fine-tip forceps 1 mm distal from the eyeball. To visu-
alize TdTomato-labeled RGC axons, we perfused mice with PBS followed by
4%paraformaldehyde/10% sucrose/PBS. Optic nerves were post-fixed in 4%
paraformaldehyde/PBS overnight. Nerves were mounted in Fluoromount-G,
and the nerve segments were scanned by confocal microscope. The z stack
images were deconvoluted by AutoQuant software.
Immunohistochemistry
Neuronal cultures were fixed in 4% (w/v) paraformaldehyde/10% sucrose/
PBS at room temperature for 15 min, followed by permeabilization with
0.1% Triton X-100/PBS for 30 min. After blocking for 1 hr with 5% BSA/
0.1% Triton X-100/PBS, axons were then stained with anti-Tuj1 (1:2,000)
and anti-neurofilament-M (NF-M; 1:1,000) in blocking buffer at 4C overnight.
After washing three times with 0.1% Triton X-100/PBS, axons were labeledwith the appropriate Alexa-dye-conjugated secondary antibodies (Life Tech-
nologies) for 2 hr at room temperature, washed three times with 0.1% Triton
X-100/PBS, and mounted in Fluoromount-G.
In Situ Hybridization
The eyeballs from P6 mice were fixed in 4% paraformaldehyde/PBS at 4C
overnight, then cryopreserved in a 1:2 mixture of 30% sucrose/PBS:OCT for
15-mm cryosections. Sections were post-fixed for 10 min in 4% paraformalde-
hyde, washed in PBS, and treated with PBS containing a final concentration of
10mg/mLproteinaseK (Invitrogen) at room temperature for 2min. The sections
were then post-fixed for 5 min in 4% paraformaldehyde, washed in PBS, and
permeabilized in 1% Triton X-100/PBS for 30 min. After blocking for 2 hr at
room temperaturewith hybridizationbuffer (50% formamide, 53 saline-sodium
citrate [SSC], 13 Denhardt’s, 250 mg/ml yeast tRNA, and 500 mg/ml herring
sperm DNA), the sections were hybridized with digoxigenin-labeled antisense
or sense probes at 72C overnight. The sections were washed in 0.23 SSC at
72C for 90 min and then blocked in buffer containing 100 mM Tris-Cl (pH 7.6),
150 mM NaCl, and 10% heat-inactivated goat serum for 1 hr. The hybridized
probes were detected by alkaline-phosphatase-conjugated anti-digoxigenin
antibody (Roche) and revealed by chromogenic substrate nitro blue tetrazo-
lium/5-bromo-4-chloro-3-indolyl-phosphate (NBT/BCIP; Roche).
Statistical Analysis
Statistical analysis was performed using Student’s t test or two-way ANOVA
post hoc test. The p values more than 0.05 were considered not significant.
Data are expressed as mean ± SD.
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